NCT06361186已完成1 期
A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Proximod in Healthy Subjects.
Longevity Inc.1 个研究点 分布在 1 个国家目标入组 134 人开始时间: 2017年9月14日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 134
- 试验地点
- 1
- 主要终点
- Peak plasma concentration (Cmax)
研究概览
简要总结
The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects. The main questions it arms to answer are:
- to evaluate the safety and tolerance of Proximod in healthy subjects after single or repeated doses.
- to learn the pharmacodynamics of Proximod in healthy subjects after single or repeated doses.
- to evaluation of the effect of food on the pharmacokinetics of Proximod in healthy subjects Participants will receive test tablets or placebo at the indicated date and collect blood samples.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Before the test, sign an informed consent form and fully understand the written test content, process and possible adverse reactions.
- •Complete research in accordance with the requirements of the trial plan.
- •Subjects (including partners) are willing to have no pregnancy plans in the next 6 months and voluntarily take effective contraceptive measures.
- •Male and female subjects aged 18 to 50 years old (including 18 and 50 years old).
- •Male subjects must weigh no less than 50 kg, and female subjects must weigh no less than 45 kg. Body mass index (BMI) = weight (kg)/height 2 (m2), body mass index is in the range of 18~28kg/m2 (including the critical value).
- •Health status: No clinically significant history of heart, liver, kidney, digestive tract, nervous system, respiratory system (such as asthma, exercise-induced asthma, chronic obstructive pulmonary disease), mental disorder, metabolic abnormality, etc.
- •Normal physical examination and vital signs or abnormal without clinical significance.
排除标准
- •Those who smoked more than 5 cigarettes per day in the 3 months before the test.
- •Have a history of allergy to the trial drug or its excipients, or allergic constitution (allergy to multiple drugs and food).
- •Have a history of drug and/or alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine).
- •Blood donation or significant blood loss (>450 mL) within three months before screening.
- •Taking any drugs that alter liver enzyme activity 28 days before screening.
- •Take any prescription drugs, over-the-counter drugs, any vitamin products or herbal medicines within 14 days before screening.
- •Those who have taken special diets (including dragon fruit, mango, grapefruit, etc.) or engaged in strenuous exercise within 2 weeks before screening, or other factors that affect drug absorption, distribution, metabolism, excretion, etc.
- •Concomitant inhibitors or inducers of CYP3A4, P-gp or Bcrp such as itraconazole, ketoconazole or dronedarone.
- •Recent significant changes in eating or exercise habits.
- •Participated in a drug clinical trial within three months before taking the study drug.
- •Have a history of dysphagia or any gastrointestinal disease that affects drug absorption.
- •Suffering from any disease that increases the risk of bleeding, such as acute gastritis or gastric and duodenal ulcers.
- •ECG abnormalities have clinical significance or QTC>470ms in men or QTC>480ms in women.
- •Abnormal and clinically significant ophthalmic examination, including fundus examination, optical coherence tomography.
- •Female subjects are lactating or have positive serum pregnancy results during the screening period or during the trial.
- •Clinically significant abnormalities in clinical laboratory tests or other clinically significant following diseases diagnosed within 12 months (including but not limited to gastrointestinal, renal, liver, neurological, blood, endocrine, tumor, lung, immune, psychiatric or Cardiovascular disease).
- •Positive screening results for viral hepatitis (including hepatitis B and hepatitis C), HIV antibodies, and Treponema pallidum antibodies.
- •Acute illness or concomitant medication occurs from the screening stage to study medication.
- •Ingested chocolate, any caffeinated or xanthine-rich food or drink 24 hours before taking study drug.
- •Positive alcohol breath test 24 hours before taking study medication or upon check-in.
- •Those with a positive urine drug screen or a history of drug abuse within the past five years or 3 years before the test.
- •Intolerance to standard meals (two boiled eggs, a piece of toast with buttered bacon, a box of fried potato chips, a glass of whole milk).
- •Subjects (this article only applies to subjects participating in postprandial trials).
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo tablet, qd, oral administration for 28 days
干预措施: Placebo (Drug)
test drug
Experimental
Proximod Tablets, 6mg and 12mg, qd, oral administration for 28 days
干预措施: Proximod (Drug)
结局指标
主要结局
Peak plasma concentration (Cmax)
时间窗: Up to 64 days
Time to peak plasma concentration (Tmax)
时间窗: Up to 64 days
The lowest plasma concentration (Cmin)
时间窗: Up to 64 days
Half-life (t1/2)
时间窗: Up to 64 days
Number of adverse events and number of participants with adverse events
时间窗: Up to 64 days
次要结局
- Lymphocyte count(Up to 64 days)
- Percentage of CD3+CD4+ and CD3+CD8+ T cells(Up to 64 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Ethoximod Pharmacokinetics In Healthy SubjectsPsoriasisNCT06361212Longevity Inc.65
已完成
1 期
Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT06361199Longevity Inc.22
已完成
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy SubjectsGoutHyperuricemiaNCT03906006Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.32
已完成
1 期
Single Ascending Dose Study of 9MW3011 in Chinese Healthy SubjectHealthyNCT06389942Mabwell (Shanghai) Bioscience Co., Ltd.48
已完成
1 期
First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male SubjectsHealthyNCT05018403Aptarion Biotech AG40